Imunoterapija raka debeloga crijeva by Antonio Juretić
127
Rad 533. Medical Sciences, 45 (2018) : 127-138
A. Juretić: Colorectal cancer immunotherapy
COLORECTAL CANCER IMMUNOTHERAPY
Antonio Juretić
Department of Clinical Oncology, School of Medicine, University of Zagreb, Za-
greb, Croatia; Oncology Clinic, University Hospital Centre Zagreb, Zagreb, Croatia
Summary
Recent successful results of a relatively new immunotherapeutic anti-cancer strategy based 
on the blockade of immune inhibitory pathways by monoclonal antibodies against checkpoint 
molecules can be considered as a medical breakthrough in clinical cancer immunotherapy. This 
type of immunotherapy became a standard part of systemic therapy protocols in the treatment of 
some metastatic solid tumors such as melanoma, non-small cell lung cancer, genitourinary can-
cers, Merkel-cell carcinoma, squamous-cell carcinoma of the head and neck, and solid tumors 
with DNA high microsatellite instability or DNA mismatch-repair deficiency. Recent progress 
in colorectal cancer genome analysis, and also supported by clinical observations, indicates 
that patients with DNA mismatch repair deficiency or microsatellite instability-high metastatic 
colorectal cancers are a distinct biomarker-defined population that might benefit from immu-
notherapy treatment with monoclonal antibodies against checkpoint molecules. This treatment 
has therefore become a new treatment option for this colorectal cancer subgroup of patients. 
However, besides tumor microsatellite instability or mismatch-repair deficiency status, other pre-
dictive biomarkers are also needed since not all these tumors respond to anti-check point immu-
notherapy treatment. This paper aims to present a basic overview of immunotherapy in mismatch 
repair deficient colorectal cancer patients.
Keywords: colorectal cancer; biomarkers; immunotherapy; immunooncology; microsatellite 
instability; mismatch repair deficiency; personalized medicine.
INTRODUCTION
Colorectal cancer (CRC) is one of the most common malignant tumors and 
unfortunately also one of the leading tumor type causes of cancer death in the 
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different subtypes characterized by specific molecular and morphological alte-
rations (1-6).
A major feature of CRC is genetic instability that can arise via at least two 
different mechanisms. The most common (around 84 % of sporadic CRC) is cha-
racterized by chromosomal instability (CIN), with gross changes in chromoso-
me number and structure, including deletions, gains, translocations and other 
chromosomal rearrangements. Mutations in the adenomatous polyposis coli 
(APC) tumor suppressor gene are the most frequent mutations in this pathway. 
The second group (around 13–16 % of sporadic CRC) is hypermutated and shows 
microsatellite instability (MSI) due to defective DNA mismatch repair (MMR) 
(1-6). A hypermutated tumor is defined as a tumor with an increased mutation 
burden (a high rate of somatic mutation). The threshold above which tumors 
are considered hypermutated, however, depends on the sequencing methodo-
logy and type of cancer (1,2,7, 8). Importantly, the clinical significance of iden-
tifying hypermutated tumors has recently been demonstrated by several studies 
showing that the tumor mutation burden correlates with the generation of neo-
antigens (mutated proteins) and clinical response to immunotherapy. Causes of 
hypermutation vary across cancer types. A leading cause of the mutations fo-
und in several gastrointestinal cancers is the dysfunction in the mismatch repair 
(MMR) system. Microsatellite instability (MSI) refers to the hypermutable state 
of cells caused by impaired DNA mismatch repair (MMR). It consists of inserti-
on and deletion mutations in stretches of short tandem DNA repeats (microsa-
tellites) and of nucleotide substitutions throughout the genome. MSI-high (MSI-
H) or MMR deficient carcinomas can arise due to either a germline mutation in 
one of the genes responsible for DNA mismatch repair (Lynch syndrome (LS) 
or hereditary non-polyposis colorectal cancer (HNPCC); around 3 %) or somatic 
inactivation of the same pathway, most commonly through hypermethylation of 
the MLH1 gene (sporadic MSI-H; around 12 %). One of the most frequent genetic 
alterations in CRCs with MSI is the oncogenic BRAF V600E mutation (1-7,9,10).
Regardless of the origin (hereditary or sporadic) or type of mutation, MSI-H 
CRCs share some distinct histologic cancer features (mucin-rich, signet ring and 
medullary types, often admixed) with increased numbers of tumor infiltrating 
lymphocytes (TILs) and a prominent Crohn’s-like lymphoid reaction. MSI-H 
carcinomas are almost always located in the ascending colon. Lynch syndro-
me (LS) is a syndrome of inherited susceptibility to cancers of several organs, 
primarily the large bowel, with the next most frequently affected being the en-
dometrium. In addition, patients with Lynch syndrome have an increased risk 
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of synchronous or metachronous tumors that include extracolonic sites (small 
bowel, stomach, endometrium, skin, genitourinary tract). Prognostically, pati-
ents with MSI-H tumors, especially those with early stage disease, exhibit, due 
to the reduced rates of tumor recurrence, a more favorable outcome (overall sur-
vival) in comparison with stage-matched sporadic CRCs. Clinically, MSI-H CRC 
develops a large size tumor with high levels of cell growth but less metastasis (4-
7,9,10). It is also stated that MSI-H CRC patients are less likely to respond to flu-
oropyrimidine chemotherapy than microsatellite stable (MSS) tumor patients, 
but this conclusion remains controversial (4-6,11). Based on this conclusion, pa-
tients with stage II MSI-H might be spared adjuvant fluoropirimidine treatment 
due to lack of survival benefit (12).
Recent integration of various CRC gene expression-based subtypings re-
sulted in a consensus molecular CRC classification enabling the segregation 
of most tumors into one of four consensus molecular subtypes (CMS). These 
are: CMS1 (MSI-immune, 14%), CMS2 (canonical, 37%), MS3 (metabolic, 13%), 
and CMS4 (mesenchymal, 23%). The majority of CMS1 tumors are MSI tumors, 
while CMS subtypes 2 to 4 display higher rates of CIN. A critical observation 
resulting from these molecular profiling studies is that, in general, gene-specific 
abnormalities are not consistently altered within the molecular subtypes. This 
observation highlights the poor correlation between gene signature and phe-
notype in CRC and has significant implications for gene-based precision medi-
cine. For example, a mutation of the KRAS oncogene has emerged as a powerful 
biomarker predicting a lack of benefit from epidermal growth factor receptor 
(EGFR) inhibitors in metastatic CRC. On the other hand, the profiling studies 
have demonstrated that wildtype RAS status is not associated with any single 
CMS subtype. Thus, at present, this is a classification predominantly applicable 
to research rather than, as is the case with consensus breast cancer molecular 
subtypes, to routine patient care (2-7).
The treatment strategy for patients with colorectal cancer is based on the 
estimation of colorectal cancer disease stage, patient performance status, me-
dical comorbidities, patient preferences, and tumor patohistological and tumor 
molecular characteristics. Depending on these estimates and parameters, the 
approach to patient treatment can be curative or palliative. Treatment modaliti-
es include surgery, chemotherapy, radiation therapy, anti-angiogenic and anti-
EGFR therapy, either as single treatment modalities or in combination (4-6,12-15). 
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IMMUNOTHERAPY
Immunotherapy as an anti-cancer treatment modality has been used for over 
a hundred years, starting with the application of Coley’s toxin as early as the end 
of the 19th century and continuing with various immunotherapeutic approaches 
up to the present. In clinical testing and application these various immunologi-
cal approaches were usually ineffective or, when they were effective, which was 
rare, were not easily and broadly applicable and therefore not in routine use. 
The immunotherapeutic approaches were based on the assumption that tumor 
cells can be antigenically distinct from normal cells and that the host’s immuno-
logical system can recognize this antigenic difference and consequently should 
mount an anti-tumor immune response against autologous tumor cells. Some of 
these tumor antigens which can be recognized on autologous tumor cells can be 
unique to particular tumor cells, i. e. tumor specific. They might have been pro-
duced as a consequence of somatic gene mutations in tumor cells in the course 
of their malignant cell transformation or by „new“ gene formations in places of 
chromosomal translocations. Due to their generation process, these antigens are 
labeled “neoantigens“. In some cases over or aberrantly expressed normal mo-
lecules from non-mutated genes on tumor cells can act as tumor antigens. They 
then form the so-called group of tumor-associated antigens (TAAs). Examples of 
these are HER-2 molecule and cancer/testis antigens, respectively (16-22).
Only recently have clinical trials using monoclonal antibodies against immu-
ne checkpoint regulatory molecules on T-lymphocytes which function as „in-
hibitory receptors“ finally proven to be a clinical effective immunotherapeutic 
approach to the treatment of some solid tumors, namely melanoma, non-small 
cell lung cancer, genitourinary cancers, Merkel-cell carcinoma, squamous-cell 
carcinoma of the head and neck, solid tumors with high microsatellite instabi-
lity or mismatch-repair deficiency, and classic Hodgkin’s lymphoma (17-24).
Antigenic activation of adaptive immunity cells (T- or B- lymphocytes) after 
antigen recognition through the antigen-specific receptor (the so-called “first si-
gnal“) includes, besides cytokine participation, cell-cell regulatory interactions 
with cell membrane bound costimulatory or coinhibitory molecules on other 
cells (the so-called “second signal“). A second co-stimulatory signal is essential 
for lymphocyte activation, but there are also co-inhibitory regulatory molecules 
and pathways having the physiological role of dampening lymphocyte activa-
tion because a too strong immune activation or reactions can cause, as a side 
effect, damage to the body’s normal cells (autoimmune reactions). Because of 
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this regulatory function of theirs, these membrane bound regulatory molecules 
are also called checkpoint molecules and they in fact function, as has already 
been mentioned, as stimulatory or inhibitory receptors on lymphocytes (17-26).
When applied, monoclonal antibodies that are blocking co-inhibitory mole-
cules such as cytotoxic T-lymphocyte antigen 4 (CTLA-4) and programmed cell 
death 1 (PD-1) or its ligand, programmed cell death ligand 1 (PD-L1) on tumor 
cells might in part of the patients with the above mentioned tumor types non-
specifically increase antitumor immunity and thus provide a durable clinical 
response and probably also lead to some of them being cured. The first phase 
3 clinical results of studies that used blocking monoclonal antibodies against 
inhibitory receptors on T-lymphocytes appeared in 2010 and continue to be con-
ducted. The first successful results were obtained in patients with metastatic 
melanoma in whom ipilimumab, the humanized monoclonal antibody targe-
ting the inhibitory receptor molecule CTLA-4, was used. Later results, which 
were even more successful and pertained to several additional cancer types, 
were obtained by using monoclonal antibodies against the inhibitory receptor 
PD-1 or against its ligand PD-L1 (17-27). 
It should be emphasized that these monoclonal antibodies are immuno-
modulatory and this type of immune approach are not targeting tumor cells 
but instead nonspecifically (re)activating immune cells in places where some of 
them might then act against autologous tumor cells. By increasing the nonspe-
cific activity of the immune system, immune checkpoint blockade can have in-
flammatory side effects, which are often termed immune-related adverse events. 
Although any organ system can be affected, immune-related adverse events 
most commonly involve the gastrointestinal tract, endocrine glands, skin, and 
liver. The occurrence of these immune-related adverse events provides eviden-
ce that immune checkpoint blockade has activated a patient’s immune system 
but whether this immunologic activation correlates with improved antitumor 
immunity remains controversial (17-28).
Despite these practice changing results, considerable efforts are currently 
being made to identify reliable predictive biomarkers for identifying the subgro-
up of patients who might benefit from this immunotherapy approach, thus spa-
ring nonresponders the risk of severe adverse events and saving costs (29-31).
PD-L1 protein expression by tumor and immune cells has been investiga-
ted as a potential predictive biomarker but its correlation with immunotherapy 
efficacy is still debated and there are technical issues preventing its routine use 
in clinical practice. Above all, different threshold levels have been adopted for 
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identifying positive samples in different tumor types. Other promising candida-
te predictive biomarkers are currently under investigation, particularly cells or 
molecules related to the immune response in the tumor microenvironment such 
as tumor infiltrating lymphocytes (TILs), indoleamine 2,3-dioxygenase (IDO), 
BCL-2 interacting mediator of cell death-Bim, and interferon-gamma (29-31).
A correlation with immunotherapy was also found to exist in the soma-
tic mutational landscape of tumors since a high mutational burden has been 
shown to correlate with the benefit from anti-checkpoint immunotherapy. It is 
assumed that the more mutated tumors might have more neo-antigens and con-
sequently be more immunogenic and more easily recognizable by the immune 
system, thus eliciting the recruitment and activation of immune cells, as a result 
of which they might be more immunotherapeutically targetable and responsive 
(5-7,10,32-35).
When considering genomic instability across various cancer types, colorectal 
cancer falls in the middle of the pack in terms of the average tumor mutational 
load, though there is marked heterogeneity. Nevertheless, an increased rate of 
somatic mutations has been observed particularly in mismatch repair (MMR) 
deficient or microsatellite instability-high (MSI-H) tumors. These tumors can 
contain approximately 500-fold more mutations per tumor. The frameshift mu-
tations seen in MSI tumor cells create novel proteins that are a potential sour-
ce of immunogenic neo-antigens causing immune recognition and reactivity 
against themselves. Indeed, these tumors have shown responsiveness to anti-
checkpoint immunotherapy independently of histologic and anatomic defined 
subtypes. Thus, the MMR status of the tumor may represent a potentially fea-
sible and useful predictive biomarker; besides, it has a well-known prognostic 
role (5-7,10,32-35). 
The first data regarding the initial success of immune checkpoint inhibitors 
in mCRC were presented in mid-2015, when the results of the phase II KEYNO-
TE 016 trial with pembrolizumab in patients with refractory metastatic tumors 
were published. In this study three cohorts of patients were recruited: (1) cohort 
A: patients with high microsatellite instability (MSI-H) or deficient mismatch 
repair (dMMR) mCRC (n = 11); (2) cohort B: patients with microsatellite stability 
(MSS) or proficient (p)MMR mCRC (n = 21); and (3) cohort C: patients with MSI-
H non-mCRC cancers (n = 9). Immune-related objective response (iORR) rates 
were 40%, 0%, and 71% in the 3 groups, respectively; the median PFS and OS 
were not reached in cohort A; 2.2 and 5.0 months, respectively, in cohort B (HR 
for PFS = 0.10, n < 0.001, HR for OS = 0.22, n = 0.05). For the first time the activity 
133
Rad 533. Medical Sciences, 45 (2018) : 127-138
A. Juretić: Colorectal cancer immunotherapy
of an anti-PD1 was demonstrated in patients with MSI-H while no effect was 
observed in MSS mCRC patients (36). As a possible explanation for such results, 
it was demonstrated that tumors with MSI-H are characterized by a high burden 
of somatic mutations that can be recognized by the patient’s immune system. 
After this initial promising study, the later study included not only CRC pati-
ents but also patients with other advanced MMR-deficient cancers, i.e. across 12 
different tumor types. Objective radiographic responses were observed in 53% 
of patients and complete responses were achieved in 21% of patients. Respon-
ses were durable with median progression-free and overall survival still not 
reached. Functional analysis in a responding patient demonstrated rapid in vivo 
expansion of neoantigen-specific T cell clones that were reactive to mutant neo-
peptides found in the tumor (37). These data support the hypothesis that the 
large proportion of mutant neo-antigens in MMR-deficient cancers makes them 
sensitive to immune checkpoint blockade, regardless of the cancers’ tissue of 
origin (6,32-37).
Based on this and some other data, on May 23, 2017, the U.S. Food and Drug 
Administration granted accelerated approval to pembrolizumab for adult and 
pediatric patients with unresectable or metastatic, microsatellite instability-high 
(MSI-H) or mismatch repair deficient (dMMR) solid tumors that have progre-
ssed following prior treatment and who have no satisfactory alternative tre-
atment options or with MSI-H or dMMR colorectal cancer that has progressed 
following treatment with a fluoropyrimidine, oxaliplatin, and irinotecan. This is 
the FDA’s first tissue/site-agnostic approval (38).
The approval was based on data from 149 patients with MSI-H or dMMR 
cancers enrolled across five uncontrolled, multi-cohort, multi-center, single-arm 
clinical trials. Ninety patients had colorectal cancer and 59 patients were diagno-
sed with one of 14 other cancer types. Patients received either pembrolizumab, 
200 mg every 3 weeks, or pembrolizumab, 10 mg/kg every 2 weeks. Treatment 
continued until unacceptable toxicity, or disease progression that was either 
symptomatic, rapidly progressive, required urgent intervention, or associated 
with a decline in performance status. A maximum of 24 months of treatment 
was administered (38).
The major efficacy outcome measures were objective response rate (ORR) 
assessed by blinded independent central radiologists’ review according to RE-
CIST 1.1, and response duration. ORR was 39.6% (95% CI: 31.7, 47.9). Responses 
lasted six months or more for 78% percent of those who responded to pembro-
lizumab. There were 11 complete responses and 48 partial responses. ORR was 
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similar irrespective of whether patients were diagnosed with CRC (36%) or a 
different cancer type (46% across the 14 other cancer types).The most common 
adverse reactions to pembrolizumab include fatigue, pruritus, diarrhea, decrea-
sed appetite, rash, pyrexia, cough, dyspnea, musculoskeletal pain, constipation, 
and nausea. Pembrolizumab is associated with immune-mediated side effects, 
including pneumonitis, colitis, hepatitis, endocrinopathies, and nephritis (37-38).
Based on „similar“ results, on July 31, 2017, the U.S. Food and Drug Admi-
nistration granted accelerated approval to nivolumab for the treatment of pati-
ents 12 years and older with mismatch repair deficient (dMMR) and microsa-
tellite instability high (MSI-H) metastatic colorectal cancer that has progressed 
following treatment with a fluoropyrimidine, oxaliplatin, and irinotecan. (39-41)
The approval was based on data from Study CA209142 (CHECKMATE 142; 
NCT 02060188), a multicenter, open-label, single arm study conducted in 53 pa-
tients with locally determined dMMR or MSI-H metastatic colorectal cancer 
(CRC) who had disease progression during, after, or were intolerant to prior 
treatment with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemothe-
rapy. This was a subset of the 74 patients who had received at least one prior 
regimen for the treatment of metastatic disease containing a fluoropyrimidine 
with oxaliplatin or irinotecan for the treatment of metastatic disease (39-41).
CONCLUSION
In conclusion, data from the above mentioned recent clinical studies su-
ggest that immunotherapy with immune-checkpoint inhibitors may represent 
a promising therapeutic strategy for patients with MMR deficient tumors, inde-
pendently of subtype, which represents a paradigmatic shift in the treatment of 
these tumors. Regrettably, the proportion of candidate patients is, however, re-
latively small, because MMR deficiency is present in a relatively low percentage 
of patients and, moreover, response can be expected only in part of them. Of re-
levance to this discussion is the problem of reliable predictive biomarkers even 
in this population of patients with high mutational burdens. This also indicates 
that the presence of the relatively high mutational burden in cancer cells does 
not by itself guarantee indisputable tumor response and that additional regu-
latory cellular and molecular interactions do have a role. Moreover, response to 
immunotherapy might not only be driven by the “genetic makeup” of the tumor 
and the way how the immune system reacts to it, but also by its regulation via 
other mechanisms including the gut microbiota. From the clinical perspective, 
135
Rad 533. Medical Sciences, 45 (2018) : 127-138
A. Juretić: Colorectal cancer immunotherapy
response evaluation of anti-checkpoint immunotherapy treated patients should 
be carefully evaluated due to the possibility of the appearance of pseudoprogre-
ssion, which should not be considered as disease progression. Also, clinicians 
should be aware of the fact that anti-checkpoint immunotherapy is accompani-
ed by a new set of side-effects that need to be recognized and correspondingly 
treated.
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Sažetak
Imunoterapija raka debeloga crijeva
Nedavni uspješni rezultati razmjerno novog imunoterapijskog pristupa baziranog na blokadi 
imunoloških inhibitornih molekularnih puteva s monoklonskim antitijelima protiv molekula kon-
trolnih točaka mogu se smatrati medicinskim iskorakom u kliničkoj onkologiji. Taj tip imunote-
rapije postao je standardni dio protokola sistemne terapije nekih metastatskih tumora poput me-
lanoma, raka nemalih stanica pluća, genitourinarnog karcinoma, karcinoma Merkelovih stanica, 
raka pločastih stanica glave i vrata i solidnih tumora s visokom mikrosatelitskom nestabilnošću 
ili manjkom popravka krivo sparenih baza DNA. Noviji rezultati molekularnih analiza genoma 
raka debelog crijeva, također poduprti kliničkim opažanjima, upućuju na to da su bolesnici s kar-
cinomima u kojih postoji izražena mikrosatelitska nestabilnost ili nemogućnost popravka krivo 
sparenih baza DNA zasebna biomarkerom definirana populacija koja može imati koristi od lije-
čenja monoklonskim antitijelima protiv imunoloških molekula kontrolnih točaka. Na temelju tih 
rezultata taj je imunoterapijski pristup postao nova terapijska opcija za tu podskupinu bolesnika 
s kolorektalnim rakom. Pa ipak, uz mikrosatelitsku nestabilnosti ili nemogućnost popravka krivo 
sparenih baza DNA potrebni su i drugi biomarkeri jer je taj imunoterapijski pristup učinkovit 
samo u dijelu tih bolesnika. Cilj je ovoga rada dati osnovni prikaz imunoterapije u tih bolesnika.
Ključne riječi: kolorektalni rak; biomarkeri; imunoterapija; imunoonkologija; mikrosatelitska 
nestabilnost; manjak popravka krivo sparenih baza DNA; personalizirana medicina.
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